# OnCo record nct07722754 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07722754/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07722754", "NCT07722754" ;
  schema:name "Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial"@en ;
  schema:alternateName "BOND-4"@en ;
  schema:description "A phase 2 trial of cetuximab, fOLFIRI (5-FU, leucovorin, irinotecan), bevacizumab (glioblastoma use) and sintilimab in colorectal cancer, run by Guangdong Provincial People's Hospital, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07722754/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07722754> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "colorectal-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/rectal-cancer/>, <https://onco.cc/cancers/colon-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/folfiri/>, <https://onco.cc/drugs/bevacizumab-glioma/>, <https://onco.cc/drugs/sintilimab/> .